Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome (PROMPT)
Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks
Sponsor: HRA Pharma
Listed as NCT02297945, this PHASE3 trial focuses on Cushing's Syndrome and remains completed. Sponsored by HRA Pharma, it has been updated 12 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Mar 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Nov 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2019 — Nov 2019 [monthly]
Recruiting PHASE3
Status: Unknown Status → Recruiting
-
Mar 2019 — May 2019 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- HRA Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ankara, Turkey (Türkiye) , Antwerp, Belgium , Barcelona, Spain , Berlin, Germany , Brussels, Belgium , Bucharest, Romania , Budapest, Hungary , Cluj-Napoca, Romania , Debrecen, Hungary , Essen, Germany and 20 more locations